Genomictree
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Genomictree is listed on KOSDAQ and classified under Industrials, Commercial Services. Its market value is US$179.7M. In FY2025 it reported revenue of US$2.8M and an operating loss of US$8.5M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Genomictree in five facts
Where is Genomictree listed and in which sector?
Genomictree (Korean name: 지노믹트리) trades under KRX code 228760 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Genomictree?
Its market capitalisation was US$179.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Genomictree's latest annual revenue and operating profit?
For fiscal year 2025, Genomictree reported revenue of US$2.8M, an operating loss of US$8.5M and a net loss of US$6.9M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 59.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Treasury share disposal: results reportTreasury Shares · May 22
- Material event report (treasury share disposal)
Genomictree disclosed a plan to sell treasury shares worth US$172K, about 0.1% of its market value.
Treasury Shares · May 19 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Genomictree reported consolidated results for FY2025: revenue of US$2.57M (+59.1% year on year), an operating loss of US$7.86M and a net loss of US$6.37M.
Earnings · Feb 9 - Treasury share disposal: results reportTreasury Shares · Jan 12
- Material event report (treasury share disposal)Treasury Shares · Jan 9